Pharma BD Deal Intelligence
Transformative scale-up that made Mylan a top-tier global generics player and delivered EpiPen as an unplanned blockbuster, but that same asset later triggered a pricing scandal, and one acquired unit (Dey/Perforomist) was written down within months of close.
Full analysis, sources & comparables →Mylan's $6.7B acquisition of Merck Generics was viewed as transformative — moving Mylan from #3 US generics player to a top-tier global specialty/generics…
EpiPen — acquired in the Merck KGaA deal — held ~90% US autoinjector share at ~$200M annual sales in 2007; Mylan grew it past $1B by 2014, eventually drawing…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 4.9B / $6.7B cash. EpiPen included. Closed Oct 2, 2007. Source: Mylan investor release, FTC, Business Standard.
Transformative scale-up that made Mylan a top-tier global generics player and delivered EpiPen as an unplanned blockbuster, but that same asset later triggered a pricing scandal, and one acquired unit (Dey/Perforomist) was written down within months of close.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Laboratories Inc. / Merck Generics (Merck KGaA) (this deal) | 2007 | $6.7B | 81 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2006 | $736M | 66 |
| Mylan Laboratories Inc. / Matrix Laboratories Limited | 2005 | $736M | 39 |
| Mylan Laboratories Inc. / King Pharmaceuticals Inc. | 2004 | $4.0B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |